Teva New Data Provide Schizophrenia Treatment Insights into Switching to risperidone Extended-Release
- Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data
- Additional data include new Phase 3 RISE and SHINE analyses demonstrating no new or unexpected safety concerns in young adults with schizophrenia treated with UZEDY
- Global ADVANCE survey findings also reveal real-world experiences and perspectives on long-acting injectable (LAI) schizophrenia treatments from healthcare professionals, caregivers and patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.